Biotechnology Strengthens IP Portfolio; Receives "Intention to Grant" Patents from European and Israeli Patent Offices

Biotechnology Strengthens IP Portfolio; Receives "Intention to Grant" Patents from European and Israeli Patent Offices

IP Protection Creates Barriers to Entry and Supports the Company's Business Opportunities

Aviv, Israel - January 7, 2020 - Cellect Biotechnology Ltd. (Nasdaq: APOP), a developer of innovative technology

which enables the functional selection of stem cells, received official communication from two jurisdictions, the European Patent

Office (EPO) and the Israeli Intellectual Property Office, regarding their intention to grant European Patent Application No.

14851547.1 and Israeli Patent Application No. 244982, respectively. These patent applications include a cell-based product and

a method of manufacturing a stem and progenitor cell population with enhanced activity by short incubation with an apoptotic ligand.

recognition from global jurisdictions validates the breadth of Cellect's technology. These latest acknowledgments are significant

as they cover the ability to activate stem cells, therefore improving stem cell products and manufacturing processes", commented

Dr. Shai Yarkoni, Chief Executive Officer of Cellect. "Our collaboration efforts with companies in Germany, Korea and Israel

have each reported similar data using our process in various tissue sources (including fat derived cells). These added protections

continue to create barriers to entry and allows us to advance our business development strategies to monetize our innovation."

Company has previously published third-party data demonstrating improved "stemness" of stem cells. Specifically, it

significantly improves both proliferation and functional capabilities of hematopoietic (HSC) and mesenchymal (MSC) stem cells

originating from bone marrow, peripheral blood, umbilical cord and adipose tissue.

believe the combination of strong IP protection and validated business collaborations support our business model and will enable

us to attract external resources to strengthen and expand our opportunities," concluded Dr. Yarkoni.

patents applications cover an ex vivo method for obtaining an improved population of stem and progenitor cells (SPC) with enhanced

engraftment characteristics by activation of TNF family receptors. The Company's previous patents covered the negative selection

exerted by the ApoGraft process and product translated into clinical safety superiority. The latest patent applications describe

and protect the positive effect that the same molecules have on stem cells and translates to the efficacy of the transplanted

cells and the yields of the manufacturing processes for clinical use).

this latest notification, the Company has 65 patent applications worldwide of which 33 are issued/allowed patents.

Cellect Biotechnology Ltd.

Biotechnology (APOP) has developed a breakthrough technology for the selection

of stem cells from any given tissue, which aims to improve a variety of stem cell-based therapies.

Company's technology is expected to provide researchers, clinical community and pharma companies with the tools to rapidly isolate

stem cells in quantity and quality allowing stem cell-based treatments and procedures in a wide variety of applications in regenerative

medicine. The Company's current clinical trial focuses on bone marrow transplantations in cancer treatment.

press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements

can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan",

"may", "should", "could", "might", "seek", "target", "will",

"project", "forecast", "continue" or "anticipate" or their negatives or variations of

these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These

forward-looking statements and their implications are based on the current expectations of the management of the Company only

and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described

in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies

do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be

interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results

to differ materially from those described in the forward-looking statements: the Company's history of losses and needs for additional

capital to fund its operations and its inability to obtain additional capital on acceptable terms, or at all; the Company's ability

to continue as a going concern; uncertainties involving any strategic transaction the Company may decide to enter into as the

result of its current efforts to explore new strategic alternatives; uncertainties of cash flows and inability to meet working

capital needs; the Company's ability to obtain regulatory approvals; the Company's ability to obtain favorable pre-clinical and

clinical trial results; the Company's technology may not be validated and its methods may not be accepted by the scientific community;

difficulties enrolling patients in the Company's clinical trials; the ability to timely source adequate supply of FasL; risks

resulting from unforeseen side effects; the Company's ability to establish and maintain strategic partnerships and other corporate

collaborations; the scope of protection the Company is able to establish and maintain for intellectual property rights and its

ability to operate its business without infringing the intellectual property rights of others; competitive companies, technologies

and the Company's industry; unforeseen scientific difficulties may develop with the Company's technology; and the Company's ability

to retain or attract key employees whose knowledge is essential to the development of its products. Any forward-looking statement

in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update

or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may

be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company

is contained under the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual Report on Form 20-F for the fiscal

year ended December 31, 2018 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website,

www.sec.gov, and in the Company's periodic filings with the SEC.

Leibovitz, Chief Financial Officer